BPC-157 dosing, reconstitution, and storage are among the most-searched practical questions in peptide research, and also among the least standardized, since no single dose, delivery form, or handling protocol for BPC-157 has been formally validated in controlled human trials. This guide walks through what the published literature actually documents, where the real gaps in the science are, and how telos rx's licensed providers make the individualized calls that population-level research alone can't. telos rx offers BPC-157 as a small subcutaneous injection and as an oral capsule, each reviewed by a provider, and your provider sets the dose and schedule.
telos rx patients never reconstitute anything. telos rx BPC-157 is compounded by a licensed US pharmacy and arrives ready to inject (or, for capsules, ready to use), already prepared at the dose your provider prescribed. There is nothing to mix and no dose to calculate; the label and your care team explain how to use and store it. The reconstitution section below describes what people buying unregulated research vials have to do, and why a prescription avoids it.
Why BPC-157's Chemistry Matters for Dosing and Storage
BPC-157 (GEPPPGKPADDAGLV) is a synthetic 15-amino-acid peptide, roughly 1,419 daltons, derived from a sequence identified in human gastric juice. A 2026 biopharmaceutical review published in Pharmaceutics, one of the few papers to evaluate BPC-157 specifically from a formulation and drug-development standpoint, describes its physicochemical profile in detail, and the picture it paints is directly relevant to how the peptide is handled outside the body, not just inside it.
A few structural facts from that review explain why handling and storage instructions exist at all:
- Gastric stability: BPC-157's N-terminal polyproline cluster forms a rigid, protease-resistant structure, which is why it remains detectable in human gastric juice even after prolonged exposure to pepsin and stomach acid. This is the physiological basis researchers cite for studying an oral form at all.
- Hydrolysis risk: The Asp10 and Asp11 junction in the sequence is flagged as the peptide's principal site of hydrolytic and succinimide-formation risk under acidic or neutral conditions. That chemistry detail underlies why prepared peptide solutions are handled cold and used within a defined window rather than left at room temperature indefinitely.
- Glycation liability: The single lysine residue in the sequence can react with reducing sugars sometimes used as bulking agents in lyophilized peptide products, which is why compounding formulations favor non-reducing alternatives like trehalose or mannitol.
- Rapid clearance: Published pharmacokinetic data, mostly from animal models, puts BPC-157's plasma half-life at under 30 minutes, even though its downstream biological effects are studied over a period of hours to days.
The same review is candid about a limitation worth stating plainly: no pharmaceutical-grade formulation of BPC-157 has been developed or formally validated, and no forced-degradation or shelf-life study specific to BPC-157 solutions has been published. That doesn't mean handling instructions are arbitrary, since they're extrapolated from general peptide chemistry and the compound's known degradation risks. It does mean patients should follow the specific instructions and beyond-use date provided by their dispensing pharmacy rather than a generic timeline found online.
Preclinical and Early Human Dosing Data
Almost everything known about BPC-157 dosing comes from two very different sources: rodent studies using intraperitoneal injection, and a single small human pilot study. The figures below describe research protocols only. They are not a dosing recommendation.
A 2019 rat study on spinal cord injury, for example, tested single doses of 2 μg/kg and 200 μg/kg administered intraperitoneally, a 100-fold range that itself illustrates how unsettled dose-response data still is in animal models. Other published rodent studies have used doses spanning from roughly 10 μg/kg down to the nanogram-per-kilogram range, depending on the injury model and outcome measured.
On the human side, the only published intravenous dosing data comes from a 2025 pilot study in Alternative Therapies in Health and Medicine, which examined intravenous BPC-157 in two adults with prior BPC-157 experience: 10 mg on day one and 20 mg on day two, each diluted in saline and infused over an hour. The study reported no side effects and no measurable impact on cardiac, hepatic, renal, thyroid, or glucose biomarkers. But a two-person, unblinded pilot cannot establish a safe or effective dose for the general population, and the authors themselves call for further studies.
| Data source | Documented research dose | Route | What it does not establish |
|---|---|---|---|
| Perovic et al., 2019 (rat model) | 2 or 200 μg/kg, single dose | Intraperitoneal | Human equivalent dosing; animal-to-human extrapolation is not linear |
| Multiple rodent studies (various models) | About 10 ng/kg to 10 μg/kg | Intraperitoneal or oral (drinking water) | A standardized "effective dose" across conditions |
| Lee & Burgess, 2025 (human pilot, n=2) | 10 mg day 1, 20 mg day 2 | Intravenous infusion | Safety or dosing guidance for subcutaneous injection or any oral form |
The takeaway isn't a number, it's the gap. Rodent doses are measured in micrograms per kilogram; the one published human IV study used milligram-scale infusions in two people. There is no controlled human dose-ranging study connecting the two, which is precisely why compounded BPC-157 is dosed on an individualized basis by the prescribing provider, not from a published chart.
BPC-157 Injection: Reconstitution, and Why telos rx Patients Skip It
Compounded BPC-157 injection from telos rx arrives ready to inject, already prepared by a licensed US pharmacy at the dose your provider prescribed, so there is nothing to mix and no dose to calculate. Reconstitution is still widely searched because unregulated research BPC-157 is usually sold as a lyophilized (freeze-dried) powder, and buyers have to add a diluent such as bacteriostatic water themselves and work out the concentration. The table below shows that arithmetic as an illustration only, not a dosing recommendation, and it is not something a telos rx patient does.
| Vial strength (example) | Bacteriostatic water added | Resulting concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL |
| 5 mg | 5 mL | 1 mg/mL |
| 10 mg | 2 mL | 5 mg/mL |
| 10 mg | 5 mL | 2 mg/mL |
Research-vial users typically add the diluent slowly down the inside wall of the vial and swirl rather than shake, since vigorous agitation can denature or aggregate peptide chains. Each of those home steps (the volume of diluent, the concentration maths, the syringe reading) is a point where an error can change the dose, and unregulated vials have no pharmacy label or prescriber behind them. A prescription avoids all of it: every preparation dispensed through telos rx's licensed US compounding pharmacy partner arrives ready to inject, labeled with its concentration and beyond-use date, and your care team explains how to use and store it.
Storage: How Each Form Is Kept
Storage requirements differ by form. Your telos rx preparation arrives ready to use, so store it as the label directs:
| Form | Documented handling convention |
|---|---|
| Ready-to-inject solution (telos rx injection) | Usually refrigerated (approximately 36 to 46°F, or 2 to 8°C); protected from light; not refrozen; used within the beyond-use date on the pharmacy label |
| Oral capsules (for example, BPC-157 capsules) | Generally room temperature, tightly sealed, away from heat, light, and humidity, per the dispensing pharmacy's label |
As noted above, no controlled stability study specific to BPC-157 solutions has been published in the peer-reviewed literature. The cold-chain and light-protection conventions above are drawn from the peptide's known chemistry (its hydrolysis and glycation liabilities) and from general compounding-pharmacy practice for peptide products, not from a BPC-157-specific shelf-life trial. The beyond-use date assigned by your dispensing pharmacy, which factors in USP compounding standards, is the number that matters for your specific preparation, not a generic figure from a forum or blog post.
BPC-157 Capsules: What the Oral Research Does and Doesn't Show
You'll see oral BPC-157 capsules discussed widely, so it's worth being clear: telos rx offers BPC-157 as a subcutaneous injection and as an oral capsule, each reviewed by a provider. If BPC-157 capsules are prescribed, your provider sets the dose and timing. The section below explains what the oral research does and doesn't show.
The rationale for studying an oral form rests on that same gastric-stability property described above: unlike most peptides, which are broken down almost immediately by stomach acid and pepsin, BPC-157's polyproline-rich structure allows it to survive that environment intact for an extended period. That's a meaningfully different pharmacological premise than most injectable peptides, and it's the reason BPC-157 is one of relatively few peptides studied, mostly in animal models, as an oral candidate at all.
That said, oral bioavailability and absorption data in humans is considerably thinner than the injectable literature. Online and practitioner discussions describe a variety of capsule timing habits, such as taking them apart from meals or splitting them across the day, but none of these patterns comes from a validated human pharmacokinetic protocol.
On "how many capsules per day": there is no evidence-based answer, because capsule strength varies by preparation and no human dose-ranging study for an oral form has been published. If capsules are prescribed, the number and timing come from your provider.
Documented Dosage Ranges: Why There Is No Chart Here
Because this is one of the most commonly searched questions about BPC-157, it's worth explaining why this guide doesn't publish a human dosing chart. No controlled human trial has established a dose, frequency, or cycle length for subcutaneous BPC-157, and figures that circulate online are not validated. Your provider sets the dose and schedule after reviewing your intake, health history, and goals, and can adjust them over time based on how you're doing.
What a provider typically weighs includes your medical history and current medications, any history of cancer (BPC-157 is studied for angiogenesis, so a cancer history is a common reason to avoid it), pregnancy or breastfeeding, and whether you compete in tested sport. None of this is a recommendation, an assurance of any outcome, or a substitute for individualized dosing set by your prescribing provider.
What About a BPC-157 + TB-500 Blend Dosage Calculator?
Some patients search for a combined BPC-157 + TB-500 "blend" dosage calculator, sometimes referred to informally as the "Wolverine stack." There is no validated combined-dose calculator, because neither peptide has an established human dose. TB-500 is a short synthetic fragment based on the actin-binding region of thymosin beta-4, not the full protein, and like BPC-157 it is not FDA-approved for any use.
On regulatory status: in July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157 and TB-500 to the list of bulk substances that can be used in compounding. That vote is advisory and non-binding, pending FDA rulemaking. On October 28, 2026, HHS announced a temporary enforcement discretion policy covering both peptides: HHS does not intend to take enforcement action against state-licensed pharmacies that compound them under strict conditions with a valid prescription. It applies to each peptide as a single-ingredient product, it is not FDA approval, and HHS can revisit it. telos rx prescribes BPC-157, and the BPC-157 + TB-500 stack, after provider review, compounded by a licensed US pharmacy, with the stack supplied as two separate vials, so neither vial is a blend, under one provider-set plan rather than a do-it-yourself calculator. You can read more about TB-500's research background in our TB-500 tissue repair research overview.
Safety, FDA Status & Competitive Sport Rules
A few regulatory facts should frame every dosing decision:
- Not FDA-approved. BPC-157 is not FDA-approved for any use. telos rx prescribes it only as a compounded preparation, prepared by a licensed US pharmacy and dispensed by prescription after evaluation by a licensed provider. Approval is not guaranteed.
- Human clinical data is limited. As detailed above, controlled human dose-ranging trials do not exist. The bulk of the evidence base is preclinical (animal) research, much of it from one research group in Zagreb, supplemented by very small human pilot studies. No specific efficacy outcome or percentage should be inferred from animal data.
- Prohibited for competitive athletes. BPC-157 is listed under the World Anti-Doping Agency (WADA) Prohibited List in the S0 (Non-Approved Substances) category, and USADA explicitly warns athletes that its unapproved status means there is no pathway to a therapeutic use exemption. Athletes subject to WADA/USADA testing, or any organization with similar rules, should not use BPC-157 in any form.
For general background on what BPC-157 is and how it's studied, see our BPC-157 patient guide. If your interest is specifically in tendon or connective tissue recovery research, our guide to peptides studied for tendon repair compares BPC-157 against other options in that category.
How telos rx Approaches BPC-157 Evaluation
telos rx is an online-first, asynchronous telehealth service with no scheduled appointment. Rather than publishing a one-size-fits-all protocol, our process is built around individualized evaluation:
- Step 1: Complete an online intake describing your health history and goals.
- Step 2: A US-licensed provider reviews your intake and determines clinical appropriateness.
- Step 3: If appropriate, the provider issues a prescription specifying strength and directions. Your preparation arrives ready to inject at that prescribed dose, with storage instructions specific to it, so there is nothing to mix and no dose to calculate.
- Step 4: Your compounded BPC-157 injection ships discreetly, with pharmacy labeling that reflects the concentration and beyond-use date for that batch. Secure messaging with the care team is available, and plans can be paused or cancelled.
See plans, from $116 per month, on the telos rx BPC-157 injection page.
Frequently Asked Questions
What is the typical BPC-157 dosage documented in research?
There is no single documented human dosage. A 2019 rat study used single intraperitoneal doses of 2 or 200 micrograms per kilogram, while a published two-person human pilot used 10 mg on day one and 20 mg on day two by IV infusion. These research figures don't translate into a human injection protocol. Your provider sets the dose and schedule.
Do you need to reconstitute BPC-157 for injection?
Not with telos rx. telos rx BPC-157 arrives ready to inject, already prepared by a licensed US pharmacy at the dose your provider prescribed, so there is nothing to mix and no dose to calculate. Reconstitution applies to unregulated research powders, where buyers add a diluent such as bacteriostatic water themselves. As an illustration only, not a dosing recommendation, 5 mg mixed with 2 mL gives about 2.5 mg/mL. Each home step is a chance for error, which a prescription avoids.
How should BPC-157 injection be stored?
Store it as the label directs, usually refrigerated (roughly 36 to 46°F, or 2 to 8°C), protected from light, not refrozen, and used within the beyond-use date set by the dispensing pharmacy. No peer-reviewed shelf-life study specific to BPC-157 solutions has been published, so the date on your pharmacy label should be treated as authoritative.
How many BPC-157 capsules should I take per day?
There is no evidence-based capsule count, because no human dose-ranging study for an oral form has been published and capsule strength varies by preparation. telos rx offers BPC-157 as an oral capsule and as a subcutaneous injection; if capsules are prescribed, your provider sets how many and when.
When is the best time to take BPC-157 capsules?
No validated human timing protocol exists for oral BPC-157. Practitioner discussions describe various habits, such as taking capsules apart from meals, but these are not based on human pharmacokinetic studies. If telos rx capsules are prescribed, timing and frequency are set by your provider, as they are for the injection.
Is there a validated dosage calculator for a BPC-157 + TB-500 blend?
No. Neither peptide has an established human dose, so no validated combined calculator exists. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 and TB-500 to the bulk substances list for compounding, pending FDA rulemaking. Since October 28, 2026, a temporary HHS enforcement discretion policy covers each as a single-ingredient compounded product under strict conditions, which is not FDA approval. telos rx prescribes the BPC-157 + TB-500 stack after provider review, supplied as two separate vials under one provider-set plan.
Is BPC-157 approved by the FDA, and can athletes use it?
BPC-157 is not FDA-approved for any use. telos rx prescribes it as a compounded preparation after evaluation by a licensed provider. It is also on the World Anti-Doping Agency's Prohibited List under the S0 (Non-Approved Substances) category, and USADA has stated there is no therapeutic use exemption pathway for it, so athletes subject to anti-doping testing should not use it in any form.
Does injection or capsule form affect how BPC-157 works?
The two formats rest on different premises. Injectable BPC-157 bypasses the digestive tract, while oral forms rely on BPC-157's documented stability in gastric juice. Human comparative data between the two routes has not been published, so neither format's relative effect can be quantified. telos rx offers both formats, each after provider review, and your provider decides which, if either, fits you.
Ready to have a licensed provider set dosing and handling specific to you? See plans and start your online intake.
telos rx is LegitScript-certified. BPC-157 is not FDA-approved. Compounded medications are not FDA-approved and are prepared by a licensed US pharmacy under federal compounding regulations. Treatment is subject to medical approval by a licensed provider; approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.